MYELOPROLIFERATIVE NEOPLASMS TREATMENT MARKET ANALYSIS

The Global Myeloproliferative Neoplasms Treatment Market is estimated to be valued at US$ 9.4 Billion in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Analysts’ Views on Global Myeloproliferative Neoplasms Treatment Market:

Myeloproliferative neoplasms (MPNs) are types of blood cancer that begin with an abnormal mutation (change) in a stem cell in the bone marrow. The change leads to an overproduction of any combination of white cells, red cells and platelets. Type of Myeloproliferative neoplasms (MPNs) are Essential Thrombocythemia - Essential Thrombocythemia (ET) Is a rare blood disease in which the bone marrow produces too many platelets. High numbers of platelets may lead to a thrombus, a blood clot that forms in a blood vessel. Myelofibrosis - Myelofibrosis (MF) is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. Polycythemia Vera - Polycythemia Vera (PV) Is one of a related group of blood cancers known as “myeloproliferative neoplasms” (MPNs). Too many red blood cells are made in the bone marrow and, in many cases, the numbers of white blood cells and platelets are also elevated.

Figure 1. Global Myeloproliferative Neoplasms Treatment Market Share (%), By Disease Type, 2023

To learn more about this report, request sample copy

Global Myeloproliferative Neoplasms Treatment Market – Drivers

Increasing research and development activities by the market players: Increasing research and development activities by the market players is expected to prople the market growth over the forecast period. For instance, in May 4, 2023, PharmaEssentia, a pharmaceutical company, announced the initiation of its ECLIPSE PV Phase IIIb clinical trial of ropeginterferon alfa-2b-njft (BESREMi) for the treatment of polycythemia vera (PV), a rare, chronic and life-threatening blood cancer. The single-arm study will evaluate an accelerated dosing schedule for ropeginterferon alfa-2b-njft against the currently labelled dosing in 100 adults from U.S. and Canada. Moreover, the subjects will receive starting dosage of 250mcg, 350mcg at week two, with a target optimal dose of 500mcg at week four. In September 8, 2022, Silence Therapeutics, a pharmaceutical company, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of polycythemia vera.

Figure 2. Global Myeloproliferative Neoplasms Treatment Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global myeloproliferative neoplasms treatment market - Regional Analysis

Among regions, North America is expected to hold a dominant position in the global myeloproliferative neoplasms treatment market over the forecast period. North America is estimated to hold  38% of the market share in 2023. The global myeloproliferative neoplasms treatment market is expected to witness significant growth in the coming years, driven by the high prevalence of myeloproliferative neoplasms. Increasing prevalence of diseases like polycythemia vera in the region is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in May 20, 2023, the prevalence of polycythemia vera has been estimated to be approximately 22 cases per 100,000 population globally.

Global Myeloproliferative Neoplasms Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of things from one place to another.

Moreover, the according to the data published by the World Health Orgnisation in June 1, 2020, the healthcare services have been partially or completely disrupted in many countries. More than half (53%) of the countries surveyed have partially or completely disrupted services for the treatment of non communicable diseases.

Global Myeloproliferative Neoplasms Treatment Market Segmentation:

The global myeloproliferative neoplasms treatment market report is segmented by disease type, drug class, distribution channel, and region.

• By Disease Type, the market is segmented into Essential Thrombocythemia (ET), Myelofibrosis (MF), and Polycythemia Vera (PV)  Out of which, the Essential Thrombocythemia (ET) segment is expected to hold a dominant position in the global myeloproliferative neoplasms treatment market during the forecast period, and this is attributed to increasing approval of clinical trials from regulatory agencies.
• By Drug Class, the market is segmented into Tyrosine Kinase Inhibitors, Janus kinase inhibitors (JAKi), Antimetabolites, and Others (alkylating agents, etc.). Out of which, the Janus kinase inhibitors (JAKi) segment is expected to dominate the market over the forecast period, and this is attributed to increasing benefits from JAKI for the treatment of myeloproliferative neoplasms.
• By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period, and this is attributed to prevalence of myeloproliferative neoplasms.

Among all the segmentation, the Essential Thrombocythemia (ET) segment is expected to dominate the market over the forecast period.

Global Myeloproliferative Neoplasms Treatment Market - Cross Sectional Analysis:

Key players are focusing on inorganic strategies such as merger and acquisition is also expected to boost myeloproliferative neoplasms treatment market. For instance, in June 10, 2020, Menarini Group, a privately held Italy-based pharmaceutical and diagnostics company, announced the acquisition of  Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, for US$ 677 million.

Global Myeloproliferative Neoplasms Treatment Market: Key Developments

• On June 10, 2022, AbbVie, a pharmaceutical company headquartered in Illinois, U.S., announced new data from its phase 2 study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF). These preliminary findings show spleen volume and symptomatic improvement in this cohort.
• On May 26, 2022, Protagonist Therapeutics, a clinical stage biopharmaceutical company, announced new data from its ongoing phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV). It was presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from June 3, 2022.

Global Myeloproliferative Neoplasms Treatment Market: Key Trends

• Increasing Fast Track Designation Grant From Regulatory Agencies: Increasing fast track designation approval from regulatory authorities for the development of novel treatment for myeloproliferative neoplasms is expected increase the market traction over the forecast period. For instance, on September 8, 2022, Silence Therapeutics, a pharmaceutical company headquartered in London, U.K., received fast track designation from the U.S. Food and Drug Administration (FDA) for SLN124 for the treatment of polycythemia vera (PV).

Global Myeloproliferative Neoplasms Treatment Market: Restraint

• Increasing Product Recalls: Increasing product recalls due to technical glitch in final products is expected to hinder the market growth over the forecast period. For instance, on May 24, 2022, Teva Pharmaceuticals, a multinantional pharmaceutical company headquartered in Tel Aviv-Yafo, Israel, recalled thrombocythemia drug anagrelide, 0.5-mg capsules in the U.S. To conterbalence the restraint the market players should comply the regulatory guidelines to avoid product glithes.

Global Myeloproliferative Neoplasms Treatment Market - Key Players

Major players operating in the global myeloproliferative neoplasms treatment market include Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals.

Definition: Myeloproliferative neoplasms (MPNs) are types of blood cancer that begin with an abnormal mutation in a stem cell in the bone marrow. The change leads to an overproduction of any combination of white cells, red cells and platelets.